He joined a cancer vaccine trial at UCSF. The results could mark a turning point

Live updates

1. 22d ago

   Moderna and Merck mRNA Vaccine Reduces Melanoma Recurrence

   Moderna and Merck report that their joint mRNA vaccine prevents melanoma from returning. The treatment is part of a broader effort to develop vaccines against cancer, with clinical trials conducted at institutions including UCSF. While some reports describe the results as a triumph, others suggest that public enthusiasm for the vaccine is outpacing the actual mathematical data. The treatment aims to revolutionize how doctors manage cancer by preventing relapse after primary treatment.

   Why it matters

   mRNA technology, used in COVID-19 vaccines, is being adapted to target cancer cells. This shift represents a move toward personalized immunotherapy. The efficacy of these vaccines determines if cancer can be treated as a preventable recurrence.

   What is confirmed

   • Moderna and Merck developed an mRNA vaccine to prevent melanoma from returning.
   • A cancer vaccine trial was conducted at UCSF.

   Still unconfirmed

   • Public hype for the Moderna cancer vaccine exceeds the supporting mathematical evidence.
   • The vaccine results could mark a turning point in cancer treatment.

   What to watch next

   • Peer-reviewed results from the UCSF cancer vaccine trial.
   Sources used for this update (6)

   1. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
   2. The Economist — It now seems possible to vaccinate against cancer
   3. WSJ — Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math
   4. The Washington Post — What it was like to go through a trial that could revolutionize cancer treatment
   5. San Francisco Chronicle — He joined a cancer vaccine trial at UCSF. The results could mark a turning point
   6. STAT — Inside Moderna and Merck’s cancer vaccine triumph
   confidence 80%